Influence of chemotherapy on the expression of p53, HER-2/neu and proliferation markers in ovarian cancer.

EGFR/HER-targeted therapeutics in ovarian cancer. Future Med Chem (2012) 0.90

Predictive and prognostic protein biomarkers in epithelial ovarian cancer: recommendation for future studies. Cancers (Basel) (2010) 0.83

Immunologic aspect of ovarian cancer and p53 as tumor antigen. J Transl Med (2005) 0.80

Comprehensive profiling of EGFR/HER receptors for personalized treatment of gynecologic cancers. Mol Diagn Ther (2014) 0.80

Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol (1999) 40.46

T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature (1998) 12.70

B lymphocytes secrete antigen-presenting vesicles. J Exp Med (1996) 11.53

The use of general primers GP5 and GP6 elongated at their 3' ends with adjacent highly conserved sequences improves human papillomavirus detection by PCR. J Gen Virol (1995) 10.07

Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med (2001) 6.19

A general primer GP5+/GP6(+)-mediated PCR-enzyme immunoassay method for rapid detection of 14 high-risk and 6 low-risk human papillomavirus genotypes in cervical scrapings. J Clin Microbiol (1997) 6.09

The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. J Immunol (1994) 4.37

Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study. Lancet (1999) 4.24

The use of general primers in the polymerase chain reaction permits the detection of a broad spectrum of human papillomavirus genotypes. J Gen Virol (1990) 4.09

Sexually transmitted infection as a cause of anal cancer. N Engl J Med (1997) 4.05

Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer. J Pathol (2001) 3.94

A T-cell receptor gamma/CD3 complex found on cloned functional lymphocytes. Nature (1987) 3.81

Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol (1993) 3.73

Pretransplantation blood transfusion revisited. N Engl J Med (1991) 3.72

Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat Med (1995) 3.67

Direct binding of peptide to empty MHC class I molecules on intact cells and in vitro. Cell (1990) 3.44

The presence of persistent high-risk HPV genotypes in dysplastic cervical lesions is associated with progressive disease: natural history up to 36 months. Int J Cancer (1995) 3.29

Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial. Lancet (1999) 3.25

Detection of avian and mammalian oncogenic RNA viruses (oncornaviruses) by immunofluorescence. Cancer Res (1972) 3.23

Rapid detection of human papillomavirus in cervical scrapes by combined general primer-mediated and type-specific polymerase chain reaction. J Clin Microbiol (1990) 3.21

Sentinel lymph node procedure is highly accurate in squamous cell carcinoma of the vulva. J Clin Oncol (2000) 3.20

Group-specific differentiation between high- and low-risk human papillomavirus genotypes by general primer-mediated PCR and two cocktails of oligonucleotide probes. J Clin Microbiol (1995) 3.20

K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med (1990) 3.16

Protection against lethal Sendai virus infection by in vivo priming of virus-specific cytotoxic T lymphocytes with a free synthetic peptide. Proc Natl Acad Sci U S A (1991) 3.15

Decreased tumor surveillance in perforin-deficient mice. J Exp Med (1996) 3.00

Tumorigenicity of cells transformed by adenovirus type 12 by evasion of T-cell immunity. Nature (1983) 2.96

A complex of platelet glycoproteins Ic and IIa identified by a rat monoclonal antibody. J Biol Chem (1987) 2.94

Human papillomavirus--the most significant risk determinant of cervical intraepithelial neoplasia. Int J Cancer (1996) 2.91

Distribution of 37 mucosotropic HPV types in women with cytologically normal cervical smears: the age-related patterns for high-risk and low-risk types. Int J Cancer (2000) 2.86

Cost effectiveness analysis of a population based screening programme for asymptomatic Chlamydia trachomatis infections in women by means of home obtained urine specimens. Sex Transm Infect (2001) 2.85

EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer. Blood (1997) 2.85

Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer. Nat Immunol (2001) 2.79

The drug resistance-related protein LRP is the human major vault protein. Nat Med (1995) 2.78

CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy. Nat Med (1999) 2.77

Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. J Exp Med (1998) 2.72

General primer-mediated polymerase chain reaction permits the detection of sequenced and still unsequenced human papillomavirus genotypes in cervical scrapes and carcinomas. Int J Cancer (1990) 2.69

Prevalence of HPV in cytomorphologically normal cervical smears, as determined by the polymerase chain reaction, is age-dependent. Int J Cancer (1993) 2.60

Direct detection and genotyping of Chlamydia trachomatis in cervical scrapes by using polymerase chain reaction and restriction fragment length polymorphism analysis. J Clin Microbiol (1993) 2.59

Coexpression of BMI-1 and EZH2 polycomb-group proteins is associated with cycling cells and degree of malignancy in B-cell non-Hodgkin lymphoma. Blood (2001) 2.54

Serotyping and genotyping of genital Chlamydia trachomatis isolates reveal variants of serovars Ba, G, and J as confirmed by omp1 nucleotide sequence analysis. J Clin Microbiol (1998) 2.47

Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy. J Exp Med (2001) 2.46

ALK expression in extranodal anaplastic large cell lymphoma favours systemic disease with (primary) nodal involvement and a good prognosis and occurs before dissemination. J Clin Pathol (2000) 2.43

Characterization and properties of nine human ovarian adenocarcinoma cell lines. Cancer Res (1988) 2.40

CD4 T cells and their role in antitumor immune responses. J Exp Med (1999) 2.27

Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment. Blood (2000) 2.25

Immunoglobulin containing cells in inflammatory bowel disease of the colon: a morphometric and immunohistochemical study. Gut (1980) 2.24

Human papillomavirus and invasive cervical cancer in Brazil. Br J Cancer (1994) 2.23

Etiology of squamous cell carcinoma of the penis. Scand J Urol Nephrol Suppl (2000) 2.23

RNA amplification by nucleic acid sequence-based amplification with an internal standard enables reliable detection of Chlamydia trachomatis in cervical scrapings and urine samples. J Clin Microbiol (1996) 2.22

The Polycomb group protein EZH2 is upregulated in proliferating, cultured human mantle cell lymphoma. Br J Haematol (2001) 2.21

Eradication of adenovirus E1-induced tumors by E1A-specific cytotoxic T lymphocytes. Cell (1989) 2.20

Causes of cervical cancer in the Philippines: a case-control study. J Natl Cancer Inst (1998) 2.19

Campylobacter colitis: histological immunohistochemical and ultrastructural findings. Gut (1985) 2.15

PCR-based high-risk HPV test in cervical cancer screening gives objective risk assessment of women with cytomorphologically normal cervical smears. Int J Cancer (1996) 2.13

Determinants for genital human papillomavirus (HPV) infection in 1000 randomly chosen young Danish women with normal Pap smear: are there different risk profiles for oncogenic and nononcogenic HPV types? Cancer Epidemiol Biomarkers Prev (1997) 2.12

Monoclonal antibodies against human milk-fat globule membranes detecting differentiation antigens of the mammary gland and its tumors. Int J Cancer (1984) 2.12

Immunogenicity of peptides bound to MHC class I molecules depends on the MHC-peptide complex stability. J Immunol (1996) 2.11

Epstein-Barr virus-associated complement-fixing and nuclear antigens in Burkitt lymphoma biopsies. Int J Cancer (1974) 2.10

Role of HLA-A motifs in identification of potential CTL epitopes in human papillomavirus type 16 E6 and E7 proteins. J Immunol (1994) 2.07

Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides. J Immunol (1995) 2.05

Molecular evidence linking primary cancer of the fallopian tube to BRCA1 germline mutations. Gynecol Oncol (2000) 2.04

Peptide selection by MHC class I molecules. Nature (1991) 2.01

Processing of long-stored archival cervical smears for human papillomavirus detection by the polymerase chain reaction. Br J Cancer (1995) 2.00

Cooperation between cytotoxic and helper T lymphocytes in protection against lethal Sendai virus infection. Protection by T cells is MHC-restricted and MHC-regulated; a model for MHC-disease associations. J Exp Med (1986) 1.97

Improved PCR sensitivity for direct genotyping of Chlamydia trachomatis serovars by using a nested PCR. J Clin Microbiol (1994) 1.97

Use of anticontamination primers in the polymerase chain reaction for the detection of human papilloma virus genotypes in cervical scrapes and biopsies. J Med Virol (1989) 1.95

C-reactive protein colocalizes with complement in human hearts during acute myocardial infarction. Circulation (1997) 1.94

Tissue distribution and biochemical and functional properties of Tp55 (CD27), a novel T cell differentiation antigen. J Immunol (1987) 1.92

Comparison of seven immunoassays for the quantification of CA 125 antigen in serum. Clin Chem (1998) 1.90

Difference in prevalence of human papillomavirus genotypes in cytomorphologically normal cervical smears is associated with a history of cervical intraepithelial neoplasia. Int J Cancer (1991) 1.89

Reorganization of multivesicular bodies regulates MHC class II antigen presentation by dendritic cells. J Cell Biol (2001) 1.87

High endothelial differentiation in human lymphoid and inflammatory tissues defined by monoclonal antibody HECA-452. Am J Pathol (1988) 1.86

Tissue distribution of the multidrug resistance protein. Am J Pathol (1996) 1.84

Cutting edge: polycomb gene expression patterns reflect distinct B cell differentiation stages in human germinal centers. J Immunol (2000) 1.83

Activated cytotoxic T cells as prognostic marker in Hodgkin's disease. Blood (1997) 1.82

Biological evidence that human papillomaviruses are etiologically involved in a subgroup of head and neck squamous cell carcinomas. Int J Cancer (2001) 1.82

In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild-type p53. Eur J Immunol (1993) 1.79

In situ localization of lymphocyte subsets in synovial membranes of patients with rheumatoid arthritis with monoclonal antibodies. J Rheumatol (1982) 1.78

Variations among sublines of inbred AKR mice. Nat New Biol (1973) 1.78

Monoclonal antibody JSB-1 detects a highly conserved epitope on the P-glycoprotein associated with multi-drug-resistance. Int J Cancer (1988) 1.78

Sarcomatoid carcinoma of the urinary bladder. Clinicopathologic analysis of 18 cases with immunohistochemical and electron microscopic findings. Am J Surg Pathol (1994) 1.76

Immune escape of tumors in vivo by expression of cellular FLICE-inhibitory protein. J Exp Med (1999) 1.76

H-2-linked control of in vitro gamma interferon production in response to a 32-kilodalton antigen (P32) of Mycobacterium bovis bacillus Calmette-Guérin. Infect Immun (1988) 1.73

PCR based high risk HPV testing is superior to neural network based screening for predicting incident CIN III in women with normal cytology and borderline changes. J Clin Pathol (2000) 1.73

Immunochemical detection of the multidrug resistance-associated protein MRP in human multidrug-resistant tumor cells by monoclonal antibodies. Cancer Res (1994) 1.73

Unique transcription pattern of Epstein-Barr virus (EBV) in EBV-carrying gastric adenocarcinomas: expression of the transforming BARF1 gene. Cancer Res (2000) 1.72

Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction. Proc Natl Acad Sci U S A (1996) 1.72

The viral origin of cervical cancer in Rabat, Morocco. Int J Cancer (1998) 1.69

Loss of transporter protein, encoded by the TAP-1 gene, is highly correlated with loss of HLA expression in cervical carcinomas. J Exp Med (1994) 1.69